Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT04440280
PHASE2

Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy

Sponsor: Massachusetts Eye and Ear Infirmary

View on ClinicalTrials.gov

Summary

This protocol will investigate whether topical application of N-acetyl cysteine (NAC) eye drops decreases oxidative stress and confers cytoprotection in patients with FECD.

Key Details

Gender

All

Age Range

21 Years - Any

Study Type

INTERVENTIONAL

Enrollment

45

Start Date

2020-09-16

Completion Date

2027-04-30

Last Updated

2025-09-29

Healthy Volunteers

No

Interventions

DRUG

N-acetyl cysteine (NAC) 10% solution

N-acetyl cysteine is a sterile, unpreserved eye drop containing 10% (100 mg/mL) of acetylcysteine.

DRUG

N-acetyl cysteine (NAC) 20% solution

N-acetyl cysteine is a sterile, unpreserved eye drop containing 20% (200 mg/mL) of acetylcysteine.

DRUG

Visine Dry Eye Relief eye drops

Visine Tears Dry Eye Relief artificial tears ophthalmic solution

Locations (1)

Massachusetts Eye and Ear Infirmary

Boston, Massachusetts, United States